Puma Biotechnology Earnings Estimate

PBYI Stock  USD 3.14  0.12  3.97%   
By analyzing Puma Biotechnology's earnings estimates, investors can diagnose different trends across Puma Biotechnology's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Puma Biotechnology is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Puma Biotechnology is projected to generate 0.125 in earnings per share on the 31st of December 2024. Puma Biotechnology earnings estimates module stress-tests analyst consensus about projected Puma Biotechnology EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Puma Biotechnology, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Puma Biotechnology Revenue Breakdown by Earning Segment

By analyzing Puma Biotechnology's earnings estimates, investors can diagnose different trends across Puma Biotechnology's analyst sentiment over time as well as compare current estimates against different timeframes. The Puma Biotechnology's current Gross Profit Margin is estimated to increase to 0.88, while Gross Profit is projected to decrease to under 101.1 M.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Puma Biotechnology Earnings per Share Projection vs Actual

About Puma Biotechnology Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Puma Biotechnology earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Puma Biotechnology estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Puma Biotechnology fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-1.3 B-1.3 B
Retained Earnings Total Equity-1.2 B-1.3 B
Earnings Yield 0.11  0.11 
Price Earnings Ratio 9.45  9.93 

Currently Active Assets on Macroaxis

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.417
Earnings Share
0.47
Revenue Per Share
5.045
Quarterly Revenue Growth
0.435
Return On Assets
0.0973
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.